Non-immunogenic cancers have best outcomes—according to findings at the Anesthesiology 2021 annual meeting of a large retrospective study comparing 90-day survival.
An app developed by Canadians, and highlighted by a study published by JAMA Oncology, helps identify patients who may have cancer predisposition syndrome.
Patients with advanced esophageal squamous cell carcinoma (ESCC) who receive either one or two checkpoint inhibitors along with chemotherapy have significantly improved overall survival than from chemotherapy alone.
While initial studies suggest dogs could be helpful in the detection of certain diseases, University of Montreal and Institut Curie researchers are looking to improve upon those initial experiments.
Up to 40% of patients undergoing chemotherapy present with cutaneous adverse reactions. Some are so severe they can lead to a pause or reduction in cancer treatment.
Pertuzumab and trastuzumab plus paclitaxel strong survival outcomes in HER2+/HR- early breast cancer. Results from the WSG (West German Study Group)-ADAPT Her2+/HR- trial at the 2021 ASCO conference.
